Acumen Pharmaceuticals, Inc.
ABOS
$1.98
$0.052.59%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -40.83% | 46.94% | |||
| Gross Profit | 40.83% | -46.94% | |||
| SG&A Expenses | -1.73% | -9.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -36.50% | 37.47% | |||
| Operating Income | 36.50% | -37.47% | |||
| Income Before Tax | 35.41% | -42.21% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 35.41% | -42.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 35.41% | -42.21% | |||
| EBIT | 36.50% | -37.47% | |||
| EBITDA | 36.51% | -37.49% | |||
| EPS Basic | 35.40% | -42.08% | |||
| Normalized Basic EPS | 35.41% | -42.06% | |||
| EPS Diluted | 35.40% | -42.08% | |||
| Normalized Diluted EPS | 35.41% | -42.06% | |||
| Average Basic Shares Outstanding | 0.00% | 0.08% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||